{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-027331","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.032573+00:00","generated_at":"2026-06-11T21:12:04.878851+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Interpace Q2 revenue $11.0M (+49% YoY); net income $0.4M vs loss","bullets":["Q2 net revenue $11.0M, up 49% YoY; gross margin improved to 62% from 52%.","Income from continuing operations $0.4M vs loss of $2.1M in Q2 2022.","Adjusted EBITDA $1.3M vs $(1.6)M loss; cash collections $10.2M, up 23% YoY.","Test volume up 15% YoY; cash balance increased to $5.1M from $1.9M.","Company faces Novitas LCD challenge for PancraGEN test; expects resolution in months to year."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-027331","json":"https://secwatch.observer/filing/0001493152-23-027331.json","markdown":"https://secwatch.observer/filing/0001493152-23-027331.md","text":"https://secwatch.observer/filing/0001493152-23-027331.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223027331/0001493152-23-027331-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223027331/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:12:04.878851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1821ef1360aa562df63468390e4e14f357391ca3","claim":"INTERPACE BIOSCIENCES, INC. reported second quarter ended June 30, 2023 results: revenue Net Revenue was $11.0 million, net income Income from continuing operations was $0.4 million.","evidence_excerpt":"Second quarter Net Revenue was $11.0 million, a $3.6 million increase over second quarter 2022. Income from continuing operations in the second quarter of 2023 was $0.4 million, an improvement of $2.5 million from the prior year quarter's loss of $2.1 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223027331/0001493152-23-027331-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"Net Revenue was $11.0 million"},{"label":"Net income","value":"Income from continuing operations was $0.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}